论文部分内容阅读
目的:分析重度妊娠高血压疾病患者经拉贝洛尔联合硫酸镁治疗的临床效果。方法:回顾性分析我院2015年1月至2016年1月期间收治的90例重度妊娠高血压患者的临床资料,按照入院顺序将所有患者分为两组:即:研究组(45例)与对照组(45)例。对照组45例重度妊娠高血压患者给予硫酸镁治疗,研究组45例重度妊娠高血压患者给予拉贝洛尔联合硫酸镁治疗;对比两组重度妊娠高血压疾病患者的治疗前后24h尿蛋白、动脉压与母婴状况。结果:治疗之前,两组重度妊娠高血压疾病患者的24h尿蛋白、动脉压无显著差异,无统计学意义(P>0.05);治疗之后,研究组45例重度妊娠高血压疾病患者的24h尿蛋白、动脉压与母婴状况显著优于对照组,差异有统计学意义(P<0.05)。结论:重度妊娠高血压疾病患者经拉贝洛尔联合硫酸镁治疗的临床效果十分显著,值得在临床上推广运用。
Objective: To analyze the clinical effect of labetalol combined with magnesium sulfate in patients with severe pregnancy-induced hypertension. Methods: The clinical data of 90 patients with severe pregnancy-induced hypertension admitted in our hospital from January 2015 to January 2016 were retrospectively analyzed. All patients were divided into two groups according to admission order: the study group (45 cases) and Control group (45 cases). Forty-five patients with severe pregnancy-induced hypertension in the control group were treated with magnesium sulfate. In the study group, 45 patients with severe pregnancy-induced hypertension were treated with labetalol plus magnesium sulfate. Compared with 24 hours before and after treatment, patients with severe pregnancy- Pressure and maternal and child conditions. Results: Before treatment, there was no significant difference in 24h urinary protein and arterial pressure between the two groups with severe pregnancy-induced hypertension (P> 0.05). After treatment, the 24-hour urine of 45 severe pregnancy-induced hypertension patients Protein, arterial pressure and maternal and infant status were significantly better than the control group, the difference was statistically significant (P <0.05). Conclusion: The clinical effect of labetalol combined with magnesium sulfate in patients with severe pregnancy-induced hypertension is significant and worthy of clinical application.